BioSpace News Archive

Critically ill patients treated with ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) within 60 hours of ICU admission experienced a survival rate double that of patients treated after being in the ICU for 60 or more hours, according to a newly released study.

PharmaMar (MSE: PHM) has announced today the publication of an article in the Life Science Alliance journal, entitled “Pre-clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19"[1] which includes a study on the in vitro activity of plitidepsin against the main SARS-CoV-2 variants, including the current Omicron variant.

Medical device and technology company Lazurite Holdings LLC today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its ArthroFree™ wireless camera system for minimally invasive surgery, and that the submission has been accepted for review.

Neutron Therapeutics, and Cosylab, today announced the close of a strategic collaboration and investment agreement to incorporate Cosylab’s OncologyOne radiation therapy product suite into Neutron’s nuBeam® BNCT systems at hospitals around the world.

Aras, which provides the most powerful low-code platform with applications to design, build, and operate complex products, today announced the merger of Minerva Group, the leading Aras Innovator PLM implementation partner.

Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has access to OXLUMO™ (lumasiran), managed by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company.

Scitara Corp, a proven innovator in laboratory digital transformation, today announces the closing of its Series B round with an additional investment of $15m.

Panavance Therapeutics Inc. (“Panavance”) is a new clinical-stage pharmaceutical company created to advance and develop GP-2250, a patented, novel therapeutic for the treatment of cancer and other therapeutic indications.

AlivaMab Discovery Services, LLC, a leader in the discovery of superior antibody-based therapeutics, announced Jane Seagal, PhD, has joined the company as Vice President of Antibody Discovery.

Will make it possible to ease patients’ life by reduced tablet burden and lower the environmental impact from toxic drug waste.